Acute Myelogenous Leukemia  >>  dexamethasone 
Welcome,         Profile    Billing    Logout  

7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dexamethasone / Generic mfg.
DEXAML-03, NCT03765541 / 2018-001467-23: Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

Recruiting
3
142
Europe
Dexamethasone, Amsacrine, Cytarabine, Azacitidine
University Hospital, Toulouse
Relapsed or Refractory Acute Myeloid Leukemia
12/25
12/25
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
06/24
 
ISAKIDS, NCT03860844 / 2018-002697-45: Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Hourglass Jan 2022 - Dec 2022 : From trial in pediatrics with r/r AML/ALL
Terminated
2
67
Europe, US, RoW
Isatuximab, SAR650984, Sarclisa, Dexamethasone or equivalent, Fludarabine, Cytarabine, Liposomal daunorubicin, Daunorubicin (nonliposomal), Idarubicin, Filgrastim or equivalent, Mitoxantrone, Doxorubicin, Vincristine, Pegaspargase (PEG) Asparaginase, Cyclophosphamide, Etoposide, Methotrexate, L - Asparginase, Hydroxyurea, L - Asparaginase (Erwinase)
Sanofi
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
09/22
05/23
NCT01084252 / 2013-001418-13: Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Checkmark For multiple myeloma in Japanese patients
Jun 2019 - Jun 2019: For multiple myeloma in Japanese patients
Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Completed
1/2
351
Europe, US, RoW
Isatuximab SAR650984, Sarclisa, Dexamethasone
Sanofi
Hematological Malignancy
12/18
07/23
KCP-8602-801, NCT02649790: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Checkmark From trial for myelodysplastic syndrome at ASH 2019
Dec 2019 - Dec 2019: From trial for myelodysplastic syndrome at ASH 2019
Active, not recruiting
1/2
277
Europe, Canada, US, RoW
KPT-8602, Eltanexor, ASTX727, Dexamethasone
Karyopharm Therapeutics Inc
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
08/24
12/24
CCS1477-02, NCT04068597 / 2019-000104-15: Study to Evaluate CCS1477 in Haematological Malignancies

Recruiting
1/2
250
Europe, US
CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax
CellCentric Ltd.
Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
06/25
06/25
NCT02494882: Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

Active, not recruiting
1
12
US
Ruxolitinib, Dasatinib, Dexamethasone
Memorial Sloan Kettering Cancer Center, Incyte Corporation, Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia
06/25
06/25

Download Options